Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine

Department of Pediatrics, University of Ferrara, Italy.bre@unife.it

BACKGROUND AND OBJECTIVES: Seven Italian centers reported data on survival, causes of death and appearance of complications in patients with thalassemia major. The interactions between gender, birth cohort, complications, and ferritin on survival and complications were analyzed. DESIGN AND METHODS: Survival after the first decade was studied for 977 patients born since 1960 whereas survival since birth and complication appearance was studied for the 720 patients born after 1970. Better survival was demonstrated for patients born in more recent years (p<0.00005) and for females (p=0.0003); 68% of the patients are alive at the age of 35 years. In the entire population 67% of the deaths were due to heart disease. RESULTS: There was a significant association between birth cohort and complication-free survival (p<0.0005). The prevalence of complications was: heart failure 6.8%, arrhythmia 5.7%, hypogonadism 54.7%, hypothyroidism 10.8%, diabetes 6.4%, HIV infection 1.7%, and thrombosis 1.1%. Lower ferritin levels were associated with a lower probability of heart failure (hazard ratio =3.35, p<0.005) and with prolonged survival (hazard ratio = 2.45, p<0.005), using a cut-off as low as 1,000 ng/mL. INTERPRETATION AND CONCLUSIONS: Survival and complication-free survival of patients with thalassemia major continue to improve, especially for female patients born shortly before or after the availability of iron chelation.

This article has been cited by other articles:

				L. J. Noetzli, S. M. Carson, A. S. Nord, T. D. Coates, and J. C. Wood Longitudinal analysis of heart and liver iron in thalassemia major Blood, October 1, 2008; 112(7): 2973 - 2978. [Abstract] [Full Text] [PDF]

				E. Angelucci and F. Pilo Treatment of hepatitis C in patients with thalassemia Haematologica, August 1, 2008; 93(8): 1121 - 1123. [Full Text] [PDF]

				J. C. Wood, R. Origa, A. Agus, G. Matta, T. D. Coates, and R. Galanello Onset of cardiac iron loading in pediatric patients with thalassemia major Haematologica, June 1, 2008; 93(6): 917 - 920. [Abstract] [Full Text] [PDF]

				P. B. Walter, E. A. Macklin, J. Porter, P. Evans, J. L. Kwiatkowski, E. J. Neufeld, T. Coates, P. J. Giardina, E. Vichinsky, N. Olivieri, et al. Inflammation and oxidant-stress in {beta}-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial Haematologica, June 1, 2008; 93(6): 817 - 825. [Abstract] [Full Text] [PDF]

				E. Vichinsky Oral Iron Chelators and the Treatment of Iron Overload in Pediatric Patients With Chronic Anemia Pediatrics, June 1, 2008; 121(6): 1253 - 1256. [Full Text] [PDF]

				E. Angelucci, G. Barosi, C. Camaschella, M. D. Cappellini, M. Cazzola, R. Galanello, M. Marchetti, A. Piga, and S. Tura Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders Haematologica, May 1, 2008; 93(5): 741 - 752. [Abstract] [Full Text] [PDF]

				W. Li, T. Coates, and J. C. Wood Atrial dysfunction as a marker of iron cardiotoxicity in thalassemia major Haematologica, February 1, 2008; 93(2): 311 - 312. [Abstract] [Full Text] [PDF]

				A. Banerjee, S. B. Chakrabarty, S. R. Karmakar, A. Chakrabarty, S. J. Biswas, S. Haque, D. Das, S. Paul, B. Mandal, B. Naoual, et al. Can Homeopathy Bring Additional Benefits to Thalassemic Patients on Hydroxyurea Therapy? Encouraging Results of a Preliminary Study Evid. Based Complement. Altern. Med., October 29, 2007; (2007) nem161v1. [Abstract] [Full Text] [PDF]

				A. Aessopos, M. Kati, and D. Farmakis Heart disease in thalassemia intermedia: a review of the underlying pathophysiology Haematologica, May 1, 2007; 92(5): 658 - 665. [Abstract] [Full Text] [PDF]

				M.A. Tanner, R. Galanello, C. Dessi, G.C. Smith, M.A. Westwood, A. Agus, M. Roughton, R. Assomull, S.V. Nair, J.M. Walker, et al. A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance Circulation, April 10, 2007; 115(14): 1876 - 1884. [Abstract] [Full Text] [PDF]

				H. Glickstein, R. B. El, G. Link, W. Breuer, A. M. Konijn, C. Hershko, H. Nick, and Z. I. Cabantchik Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences Blood, November 1, 2006; 108(9): 3195 - 3203. [Abstract] [Full Text] [PDF]

				D. J. Pennell, V. Berdoukas, M. Karagiorga, V. Ladis, A. Piga, A. Aessopos, E. D. Gotsis, M. A. Tanner, G. C. Smith, M. A. Westwood, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis Blood, May 1, 2006; 107(9): 3738 - 3744. [Abstract] [Full Text] [PDF]

				C. Borgna-Pignatti, M. D. Cappellini, P. De Stefano, G. C. Del Vecchio, G. L. Forni, M. R. Gamberini, R. Ghilardi, A. Piga, M. A. Romeo, H. Zhao, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major Blood, May 1, 2006; 107(9): 3733 - 3737. [Abstract] [Full Text] [PDF]

				E. J. Neufeld Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions Blood, May 1, 2006; 107(9): 3436 - 3441. [Abstract] [Full Text] [PDF]

				A. R. Cohen New Advances in Iron Chelation Therapy Hematology, January 1, 2006; 2006(1): 42 - 47. [Abstract] [Full Text] [PDF]

				F. Locatelli Reduced-Intensity Regimens in Allogeneic Hematopoietic Stem Cell Transplantation for Hemoglobinopathies Hematology, January 1, 2006; 2006(1): 398 - 401. [Abstract] [Full Text] [PDF]

				D. Rund and E. Rachmilewitz {beta}-Thalassemia N. Engl. J. Med., September 15, 2005; 353(11): 1135 - 1146. [Full Text] [PDF]